Table 1.
Demographic characteristics of patients being evaluated for azathioprine-induced pancreatitis
| Variables | Preemptive genotyping cohort (n = 328) | Retrospective cohort (14) (n = 373) | P |
| Age, yr, mean (range) | 42.4 (18–86) | 41.3 (18–79) | ns |
| Female sex, n (%) | 178 (54.0) | 203 (54.4) | ns |
| Weight, kg, mean ± SD | 79.3 ± 20.6 | 76.6 ± 18.8 | ns |
| Crohn disease, n (%) | 213 (65.0) | 245 (65.7) | ns |
| Ileal | 134 (40.9) | 79 (32.2) | ns |
| Colonic | 38 (11.4) | 48 (19.6) | ns |
| Ileocolonic | 156 (47.7) | 118 (48.2) | ns |
| Ulcerative colitis, n (%) | 115 (35.0) | 128 (34.3) | ns |
| Pan-colitis | 69 (60.0) | 81 (63.3) | ns |
| Left-sided colitis | 40 (35.0) | 41 (32.0) | ns |
| Proctitis | 6 (5.0) | 6 (4.7) | ns |
| Median disease duration, yr (interquartile range) | 3.67 (11.83) | 3.96 (8.42) | ns |
| Smoking history, n (%) | 114 (34.8) | 153 (41.0) | ns |
| 5-Aminosalicylate exposure, n (%) | 145 (44.2) | 160 (42.9) | ns |
| Biologic exposure, n (%) | 189 (58.0) | 224 (60.1) | ns |
| Anti-TNF | 139 (74.0) | 197 (88.0) | 0.01 |
| Anti-integrin | 33 (17.0) | 20 (9.0) | ns |
| Anti-IL12/23 | 17 (9.0) | 7 (3.0) | ns |
| Combination therapya, n (%) | 92 (28) | 71 (18.9) | ns |
| Glucocorticoid exposure, n (%) | 286 (87.2) | 301 (80.8) | ns |
| Immunomodulator exposure, n (%) | |||
| Methotrexate | 37 (11.3) | 55 (14.7) | ns |
| Thiopurine | 328 (100.0) | 373 (100.0) | ns |
| Surgery, n (%) | 55 (16.8) | 96 (25.7) | ns |
| HLA DQA1-DRB1 AA, n (%) | 328 (100.0) | 190 (50.9) | — |
| HLA DQA1-DRB1 AC, n (%) | 0 (0.0) | 142 (38.0) | — |
| HLA DQA1-DRB1 CC, n (%) | 0 (0.0) | 41 (11.0) | — |
HLA, human leukocyte antigen; IL, interleukin; ns, not significant; TNF-α, tumor necrosis factor α.
a
Combination therapy refers to the simultaneous administration of a biologic and an immunomodulator (one of methotrexate or azathioprine).